{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:07:26Z","timestamp":1788527246437,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02525-x","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:02:15Z","timestamp":1684220535000},"page":"3038-3055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-1725","authenticated-orcid":false,"given":"Shujing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle G.","family":"Bensimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Greatsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Fukunaga-Kalabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2525_CR1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Melanoma of the Skin, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"2525_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 3.2022-April 11, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf."},{"issue":"1","key":"2525_CR3","doi-asserted-by":"publisher","first-page":"MMT39","DOI":"10.2217\/mmt-2019-0022","volume":"7","author":"R Miller","year":"2020","unstructured":"Miller R, Walker S, Shui I, Brandtmuller A, Cadwell K, Scherrer E. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manage. 2020;7(1):MMT39.","journal-title":"Melanoma Manage."},{"issue":"6","key":"2525_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392.","journal-title":"CA Cancer J Clin"},{"key":"2525_CR5","first-page":"1","volume":"20","author":"C Garbe","year":"2022","unstructured":"Garbe C, Keim U, Amaral T, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 Validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;20:1.","journal-title":"J Clin Oncol"},{"issue":"126","key":"2525_CR6","first-page":"1166","volume":"2020","author":"AS Poklepovic","year":"2019","unstructured":"Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer. 2019;2020(126):1166\u201374.","journal-title":"Cancer"},{"key":"2525_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017;82:171\u201383.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2525_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/14740338.2017.1343301","volume":"16","author":"VA Trinh","year":"2017","unstructured":"Trinh VA, Zobniw C, Hwu WJ. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017;16(8):933\u201340.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2525_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313\u201326.","journal-title":"Cell"},{"issue":"10336","key":"2525_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718\u201329.","journal-title":"Lancet"},{"issue":"11","key":"2525_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23(11):1378\u201388.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2525_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0272989X16651869","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Mak. 2017;37(4):340\u201352.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2525_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Mak. 2017;37(4):427\u201339.","journal-title":"Med Decis Mak"},{"key":"2525_CR14","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 19: partitioned survival analysis for decision modelling in health care: a critical review; 2017."},{"issue":"11","key":"2525_CR15","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389\u2013430.","journal-title":"Stat Med"},{"issue":"19","key":"2525_CR16","first-page":"1","volume":"70","author":"E Arias","year":"2022","unstructured":"Arias E, Xu J. United States Life Tables, 2019. Natl Vital Stat Rep. 2022;70(19):1\u201359.","journal-title":"Natl Vital Stat Rep"},{"key":"2525_CR17","unstructured":"National Institute for Health and Care Excellence. DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data 2013. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf."},{"issue":"4","key":"2525_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1245\/s10434-016-5642-0","volume":"24","author":"AY Lee","year":"2017","unstructured":"Lee AY, droppelmann N, panageas ks, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939\u201346.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2525_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/BF02303765","volume":"5","author":"MM Mooney","year":"1998","unstructured":"Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol. 1998;5(1):54\u201363.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2525_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.bjc.6600428","volume":"87","author":"U Hofmann","year":"2002","unstructured":"Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients\u2013monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87(2):151\u20137.","journal-title":"Br J Cancer"},{"key":"2525_CR21","unstructured":"National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [TA569] 2019. https:\/\/www.nice.org.uk\/guidance\/ta569."},{"key":"2525_CR22","unstructured":"National Institute for Health and Care Excellence. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [TA632] 2020. https:\/\/www.nice.org.uk\/guidance\/ta632."},{"key":"2525_CR23","unstructured":"National Institute for Health and Care Excellence. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [TA761] 2022. https:\/\/www.nice.org.uk\/guidance\/ta761."},{"key":"2525_CR24","unstructured":"National Institute for Health and Care Excellence. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer [TA746] 2021. https:\/\/www.nice.org.uk\/guidance\/ta746."},{"key":"2525_CR25","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Nivolumab (Opdivo) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy [PC0253] 2022. https:\/\/cadth.ca\/sites\/default\/files\/DRR\/2022\/PC0253%20Opdivo%20-%20CADTH%20Final%20Rec%20Final.pdf."},{"issue":"10105","key":"2525_CR26","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.","journal-title":"Lancet"},{"issue":"8","key":"2525_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","volume":"31","author":"CN Owen","year":"2020","unstructured":"Owen CN, Shoushtari AN, Chauhan D, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol. 2020;31(8):1075\u201382.","journal-title":"Ann Oncol"},{"issue":"8","key":"2525_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"key":"2525_CR29","unstructured":"AnalySource. First Databank drug pricing database. https:\/\/www.analysource.com\/."},{"key":"2525_CR30","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule 2022. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/license-agreement?destination=\/medicare\/physician-fee-schedule\/search%3F."},{"key":"2525_CR31","unstructured":"Centers for Medicare & Medicaid Services. Hospital outpatient prospective payment system 2022. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/HospitalOutpatientPPS."},{"key":"2525_CR32","unstructured":"Agency for Healthcare Research and Quality. HCUPnet, Healthcare Cost and Utilization Project: 2015 Hospital Inpatient National Statistics. http:\/\/www.hcup-us.ahrq.gov\/."},{"issue":"6","key":"2525_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/CMR.0000000000000507","volume":"28","author":"A Tarhini","year":"2018","unstructured":"Tarhini A, Ghate SR, Ionescu-Ittu R, et al. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Res. 2018;28(6):618\u201328.","journal-title":"Melanoma Res"},{"issue":"8","key":"2525_CR34","first-page":"869","volume":"25","author":"AJ Klink","year":"2019","unstructured":"Klink AJ, Chmielowski B, Feinberg B, Ahsan S, Nero D, Liu FX. Health care resource utilization and costs in first-line treatments for patients with metastatic melanoma in the United States. J Manage Care Spec Pharm. 2019;25(8):869\u201377.","journal-title":"J Manage Care Spec Pharm"},{"key":"2525_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4236\/jct.2015.610091","volume":"6","author":"A Tarhini","year":"2015","unstructured":"Tarhini A, Corman SL, Rao S, et al. Healthcare resource utilization and associated costs in patients with advanced melanoma receiving first-line ipilimumab. J Cancer Ther. 2015;6:833\u201340.","journal-title":"J Cancer Ther"},{"issue":"7","key":"2525_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/13696998.2018.1450261","volume":"21","author":"AA Dalal","year":"2018","unstructured":"Dalal AA, Guerin A, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018;21(7):649\u201355.","journal-title":"J Med Econ"},{"issue":"9","key":"2525_CR37","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/jnci\/djaa008","volume":"112","author":"S Bajaj","year":"2020","unstructured":"Bajaj S, Donnelly D, Call M, et al. Melanoma prognosis: accuracy of the American Joint Committee on Cancer staging manual eighth edition. J Natl Cancer Inst. 2020;112(9):921\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2525_CR38","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/jso.26214","volume":"122","author":"J Bleicher","year":"2020","unstructured":"Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122(8):1770\u20137.","journal-title":"J Surg Oncol"},{"key":"2525_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","volume":"119","author":"T Kanaki","year":"2019","unstructured":"Kanaki T, Stang A, Gutzmer R, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. Eur J Cancer. 2019;119:18\u201329.","journal-title":"Eur J Cancer"},{"key":"2525_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","volume":"119","author":"AMM Eggermont","year":"2019","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019;119:1\u201310.","journal-title":"Eur J Cancer"},{"key":"2525_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djx133","volume":"110","author":"S Suciu","year":"2018","unstructured":"Suciu S, Eggermont AMM, Lorigan P, et al. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II\u2013III melanoma adjuvant therapy. J Natl Cancer Inst. 2018;110:1.","journal-title":"J Natl Cancer Inst"},{"key":"2525_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2020.07.011","volume":"137","author":"E Coart","year":"2020","unstructured":"Coart E, Suciu S, Squifflet P, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer. 2020;137:171\u20134.","journal-title":"Eur J Cancer"},{"key":"2525_CR43","unstructured":"Koruth RM, Sharma R, Kanters S, Druyts E, Kirkwood JM, editors. Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. The Society for Melanoma Research, Fifteenth International Congress; 2018; Manchester, England."},{"key":"2525_CR44","first-page":"25","volume":"8","author":"WG Wong","year":"2022","unstructured":"Wong WG, Perez Holguin RA, Stahl KA, Olecki EJ, Pameijer C, Shen C. Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma. Surg Pract Sci. 2022;8:25.","journal-title":"Surg Pract Sci"},{"issue":"6","key":"2525_CR45","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1200\/JCO.1997.15.6.2351","volume":"15","author":"BE Hillner","year":"1997","unstructured":"Hillner BE, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997;15(6):2351\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2525_CR46","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0959-8049(00)00304-X","volume":"36","author":"JL Gonzalez-Larriba","year":"2000","unstructured":"Gonzalez-Larriba JL, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer. 2000;36(18):2344\u201352.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2525_CR47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0959-8049(96)00413-3","volume":"33","author":"A Messori","year":"1997","unstructured":"Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer. 1997;33(9):1373\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2525_CR48","first-page":"184","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naive patients with advanced melanoma in the United States. J Manage Care Spec Pharm. 2017;23(2):184\u201394.","journal-title":"J Manage Care Spec Pharm"},{"issue":"8","key":"2525_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jval.2017.05.009","volume":"20","author":"LS Miguel","year":"2017","unstructured":"Miguel LS, Lopes FV, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2017;20(8):1065\u201373.","journal-title":"Value Health"},{"issue":"10","key":"2525_CR50","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/13696998.2019.1609485","volume":"22","author":"AG Bensimon","year":"2019","unstructured":"Bensimon AG, Zhou ZY, Jenkins M, et al. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. J Med Econ. 2019;22(10):981\u201393.","journal-title":"J Med Econ"},{"issue":"7","key":"2525_CR51","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40261-020-00922-6","volume":"40","author":"AG Bensimon","year":"2020","unstructured":"Bensimon AG, Zhou ZY, Jenkins M, et al. An Economic evaluation of pembrolizumab versus other adjuvant treatment strategies for resected high-risk stage III melanoma in the USA. Clin Drug Investig. 2020;40(7):629\u201343.","journal-title":"Clin Drug Investig"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02525-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T01:16:48Z","timestamp":1686791808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02525-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02525-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}